Decreased tumor expression of the IR, combined with reduction in PI3K and Ras-MAPK signaling following metformin administration, points to the indirect insulin-dependent effects of metformin as its mechanism of antitumor action in the neoadjuvant setting. Here, INS is linked to neoplasm.